Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Carol Moreno, MD, PhD, on the Phase 3 trial examining ibrutinib + rituximab versus FCR in CLL

Dr. Moreno, Hematologist, Autonomous University of Barcelona, describes the outcomes of the Phase 3 study investigating 1st line ibrutinib and rituximab versus FCR in younger chronic lymphocytic leukemia (CLL) patients presented at the 2018 ASH Annual Meeting and Exposition

Tags: ASH Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Published: 18 December 2018

Recent Videos: Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

video

Paul M. Barr, MD, elaborates on outcomes from the RESONATE trial in relapsed/refractory CLL

Dr. Barr, Associate Professor of Medicine, Director of the Clinical Trials Office, Wilmot Cancer Institute, tells us about the results ...

video

Paul M. Barr, MD, on data from the CLL-14 trial in chronic lymphocytic leukemia

Dr. Barr, Associate Professor of Medicine, Director of the Clinical Trials Office, Wilmot Cancer Institute, explains data from the recent ...

video

Paul M. Barr, MD, offers opinion on ibrutinib in 1st line chronic lymphocytic leukemia

Dr. Barr, Associate Professor of Medicine, Director of the Clinical Trials Office, Wilmot Cancer Institute, offers opinion on ibrutinib in ...

video

Daniel J. DeAngelo, MD, PhD, comments on how to manage MDS patients ineligible for transplant

Dr. DeAngelo, Chief, Division of Leukemia, Institute Physician, Professor of Medicine, Harvard Medical School, comments on how to manage myelodysplastic ...

video

Daniel J. DeAngelo, MD, PhD, considers the implications of the recent wave of approvals in AML

Dr. DeAngelo, Chief, Division of Leukemia, Institute Physician, Professor of Medicine, Harvard Medical School, considers how the recent wave of ...

video

Daniel J. DeAngelo, MD, PhD, on the significance of the updated data for gilteritinib in AML

Dr. DeAngelo, Chief, Division of Leukemia, Institute Physician, Professor of Medicine, Harvard Medical School, explains the significance of the updated ...

video

Naiyer Rizvi, MD, explains the role of biomarkers in lung cancer treatment planning

Dr. Rizvi, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia University Irving Medical ...

video

Daniel J. DeAngelo, MD, PhD, on the latest data involving uproleselan with chemotherapy in AML

Dr. DeAngelo, Chief, Division of Leukemia, Institute Physician, Professor of Medicine, Harvard Medical School, comments on the Phase III study ...

video

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trial

Dr. Leslie, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health, shares details regarding the CLL14 trial in chronic ...

video

Carol Moreno, MD, PhD, on the Phase 3 trial examining ibrutinib + rituximab versus FCR in CLL

Dr. Moreno, Hematologist, Autonomous University of Barcelona, describes the outcomes of the Phase 3 study investigating 1st line ibrutinib and ...

Related Videos

video-image

Paul M. Barr, MD, elaborates on outcomes from the RESONATE trial in relapsed/refractory CLL

video-image

Paul M. Barr, MD, on data from the CLL-14 trial in chronic lymphocytic leukemia

video-image

Paul M. Barr, MD, offers opinion on ibrutinib in 1st line chronic lymphocytic leukemia

video-image

Daniel J. DeAngelo, MD, PhD, comments on how to manage MDS patients ineligible for transplant

video-image

Daniel J. DeAngelo, MD, PhD, considers the implications of the recent wave of approvals in AML

video-image

Daniel J. DeAngelo, MD, PhD, on the significance of the updated data for gilteritinib in AML

video-image

Naiyer Rizvi, MD, explains the role of biomarkers in lung cancer treatment planning

video-image

Daniel J. DeAngelo, MD, PhD, on the latest data involving uproleselan with chemotherapy in AML

video-image

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trial

video-image

Carol Moreno, MD, PhD, on how the outcomes of the illUMINTATE trial impact treatment of CLL

video-image

Yana Pikman, MD, regarding research outcomes from the LEAP Consortium

video-image

Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia

video-image

Rod A. Humerickhouse, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Rod A. Humerickhouse, MD, PhD, considers testing for minimal residual disease in CLL

video-image

Rod A. Humerickhouse, MD, PhD, on MRD as a surrogate marker in chronic lymphocytic leukemia

video-image

Jason Butler, PhD, considers how vascular integrity impacts the leukemia-initiating metabolic switch

video-image

Rod A. Humerickhouse, MD, PhD, regarding potential side effects from venetoclax + rituximab in CLL

video-image

Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab

video-image

Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients

video-image

Keith Pratz, MD, on genetic testing in AML prior to the start of therapy

video-image

Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL

video-image

Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL

video-image

Keith Pratz, MD, comments on the Phase I study of gilteritinib presented at ASH 2018

video-image

Carol Moreno, MD, PhD, shares outcomes from the iLLUMINATE trial presented at ASH 2018

video-image

Keith Pratz, MD, regarding the reliability of the companion diagnostic test for FLT3

video-image

Keith Pratz, MD, describes how gilteritinib fits into treatment algorithms for AML

video-image

James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML

video-image

James McCloskey, MD, regarding molecular testing in acute myelogenous leukemia

video-image

James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients

video-image

James McCloskey, MD, describes how the FLT3 mutation influences treatment decisions in AML

video-image

James McCloskey, MD, speculates on the reliability of the companion diagnostic test for FLT3

video-image

Edward Copelan, MD, regarding gilteritinib for patients with FLT3+ AML

video-image

John Burke, MD, elaborates on the Beat AML umbrella study

video-image

John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML

video-image

John Burke, MD, elaborates on the incorporation of venetoclax into AML treatment regimens

video-image

John Burke, MD, speaks to the reliability of the FLT3 mutation test

video-image

John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment

video-image

Robert Rifkin, MD, discusses the rationale for genetically profiling AML patients

video-image

Ravi Vij, MD, on molecular testing and acute myelogenous leukemia

video-image

Samer Khaled, MD, tells us about the MEDALIST study examining myelodysplastic syndrome

video-image

Samer Khaled, MD, on incorporating venetoclax into treatment regimens for AML

video-image

Ravi Vij, MD, shares details regarding his clinical study presented at ASH 2018

video-image

Samer Khaled, MD, regarding gilteritinib in treatment of acute myelogenous leukemia

video-image

Samer Khaled, MD, shares details of his study examining the use of CAR-T therapy in ALL

video-image

Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax

video-image

Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in younger CLL patients

video-image

Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients

video-image

Keith Pratz, MD, discusses venetoclax in treatment of acute myeloid leukemia (AML)

video-image

James McClosky, MD, on using newly FDA approved gilteritinib for patients with AML

video-image

Jasmine Zain, MD, on the most exciting studies in lymphoma presented at ASH 2018

video-image

Jasmine Zain, MD, discusses novel treatment research regarding transplants at City of Hope

video-image

Jasmine Zain, MD, considers the impact of the new induction regimen in PTCL

video-image

Jasmine Zain, MD, defines successful induction regimens when treating PTCL

video-image

Jasmine Zain, MD, elaborates on the investigation of novel induction regimens in PTCL

video-image

Jasmine Zain, MD, regarding the standard of care in treatment of PTCL

video-image

Rena Feinman, PhD, considers the the role of the microbiome in cancer & response to therapy

video-image

Jason Butler, PhD, on how age-associated aberrant MAPK signaling impacts hematopoiesis

video-image

Sen Zhuang, MD, PhD, shares the research & development philosophy at Janssen

video-image

Sen Zhuang, MD, PhD, shares details from the LCAR-838M study in relapsed/refractory MM

video-image

Sen Zhuang, MD, PhD, speculates on how LCAR-838M may impact the treatment of MM

video-image

Sen Zhuang, MD, PhD, regarding the development of LCAR-B38M

video-image

Rod A. Humerickhouse, MD, PhD, elaborates on venetoclax in treatment of MM

video-image

Katja Weisel, MD, provides opinion on anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Habte Yimer, MD, considers the outcomes of the GRIFFIN study in multiple myeloma

video-image

Katja Weisel, MD, discusses current maintenance regimens in multiple myeloma

video-image

Habte Yimer, MD, speculates on the future of anti-BCMA CAR-T cell therapy

video-image

Katja Weisel, MD, elaborates on the outcomes of the TOURMALINE-MM3 study

video-image

Habte Yimer, MD, regarding the POLLUX and CASTOR studies presented at ASH 2018

video-image

Sattva Neelapu, MD, speculates on the future of CAR-T therapies in lymphoma

video-image

Katja Weisel, MD, shares outcomes of the POLLUX and CASTOR studies from ASH 2018

video-image

Habte Yimer, MD, regarding the Lyra trial in newly diagnosed multiple myeloma presented at ASH 2018

video-image

Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today

video-image

Peter Vorhees, MD, discusses the outcomes of the TOURMALINE-MM3 study in MM

video-image

Peter Vorhees, MD, discusses outcomes of the ALCYONE trial in multiple myeloma patients

video-image

Sattva Neelapu, MD, considers the use of axicabtagene ciloleucel with elderly lymphoma patients

video-image

Sattva Neelapu, MD, on real-world experience & clinical studies examining axicabtagene ciloleucel

video-image

Sattva Neelapu, MD, regarding the ZUMA-1 two-year follow-up study in DLBCL

video-image

Rafael Fonseca, MD, on the effectiveness of anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Rafael Fonseca, MD, discusses maintenance regimens for multiple myeloma

video-image

Rafael Fonseca, MD, regarding the TOURMALINE-MM3 study in multiple myeloma

video-image

Rafael Fonseca, MD, elaborates on the outcomes of the POLLUX and CASTOR studies in MM

video-image

Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patterns

video-image

Edward Copelan, MD, considers the role of allogeneic transplantation in lymphoma & multiple myeloma

video-image

Nikhil Munshi, MD, discusses the outcomes of the TOURMALINE-MM3 study in multiple myeloma

video-image

Nikhil Munshi, MD, discusses the POLLUX and CASTOR studies regarding the use of daratumumab in MM

video-image

Nikhil Munshi, MD, regarding the outcomes of the CA204-142 study from ASH 2018

video-image

Nikhil Munshi, MD, considers how ID2 function impacts oncogenesis in multiple myeloma

video-image

Andrew Pecora, MD, shares his thoughts on the necessity of allogeneic transplants to MML patients

video-image

Nizar Bahlis, MD, speculates on the future of anti-BCMA CAR-T cell therapy in MM

video-image

Nizar Bahlis, MD, describes current maintenance regimens for multiple myeloma

video-image

Nizar Bahlis, MD, discusses the outcomes of the TOURMALINE-MM3 study from ASH 2018

video-image

Nizar Bahlis, MD, regarding the impact of the POLLUX and CASTOR studies from ASH 2018

video-image

Elizabeth Budde, MD, evaluates the clinical study investigating mosunetuzumab from ASH 2018

video-image

Elizabeth Budde, MD, on how City of Hope has overcome logistical hurdles associated with CAR-T

video-image

Elizabeth Budde, MD, discusses the role of CAR-T therapies in lymphoma treatment algorithms

video-image

Robert Rifkin, MD, shares his thoughts on if a rituximab biosimilar can replace rituximab

video-image

Robert Rifkin, MD, explains whether or not anti-BCMA CAR-T cell therapy looks promising

video-image

Robert Rifkin, MD, discusses the outcomes of the TOURMALINE-MM3 study

video-image

Robert Rifkin, MD, talks about what clinical data could change the way multiple myeloma is treated

video-image

Ravi Vij, MD, considers anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Ravi Vij, MD, discusses current maintenance regimens for multiple myeloma

video-image

Ravi Vij, MD, regarding the POLLUX and CASTOR clinical studies in multiple myeloma

video-image

Andrzej Jakubowiak, MD, shares thoughts on the POLLUX and CASTOR clinical studies

video-image

Andrzej Jakubowiak, MD, PhD, discusses maintenance regimens in treatment of multiple myeloma

video-image

Andrzej Jakubowiak, MD, PhD, regarding the ALCYONE trial presented at ASH 2018

video-image

Andrzej Jakubowiak, MD, discusses the outcomes of the GRIFFIN study from ASH 2018

video-image

Chadi Nabhan, MD, MBA, on the role of advanced practice practitioners

video-image

Chadi Nabhan, MD, MBA, shares what is being done to prevent oncologist burnout

video-image

Chadi Nabhan, MD, MBA, discusses the key factors contributing to physician burnout

video-image

Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements

video-image

Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA

video-image

Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM

video-image

Sundar Jagannath, MD, regarding proteasome inhibitors in the treatment of MM

video-image

Maria-Victoria Mateos, MD, elaborates on the TOURMALINE-MM3 presented at ASH 2018

video-image

Maria-Victoria Mateos, MD, on the addition of daratumumab to revlimid/dexamethasone in MM

video-image

Sundar Jagannath, MD, considers maintenance regimens for multiple myeloma (MM) patients

video-image

Sundar Jagannath, MD, elaborates on the outcomes of CA204-142 in MM

video-image

Maria-Victoria Mateos, MD, regarding the CASTOR trial presented at ASH 2018

video-image

Maria-Victoria Mateos, MD, shares outcomes from the ALCYONE study in MM

video-image

Jeff Sharman, MD, shares his thoughts on rituximab biosimilars in follicular lymphoma

video-image

Lorenz Trumper, MD, discusses the results of ECHELON-2 in frontline PTCL

video-image

Lorenz Trumper, MD, on the current standard of care for the frontline treatment of PTCL

video-image

Lorenz Trumper, MD, speaks on the differences between B-Cell and T-Cell lymphomas

video-image

Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL

video-image

Swaminathan P. Iyer, MD, shares exciting studies regarding the treatment of PTCL from ASH 2018

video-image

Swaminathan P. Iyer, MD, on the outcomes of the ECHELON-2 study in PTCL

video-image

Andre Goy, MD, comments on the long-term outcome of acalabrutinib in MCL

video-image

Andre Goy, MD, on immunotherapy and the treatment of hematologic malignancies

video-image

Andre Goy, MD, considers checkpoint inhibitors in hematologic malignancies

video-image

Andre Goy, MD, discusses his real-world experience using axi-cel CAR-T cell therapy

video-image

Andre Goy, MD, on research regarding the use of axi-cel CAR-T cell therapy in DLBCL

video-image

Tatyana Feldman, MD, regarding improvements in the treatment of CTCL

video-image

Tatyana Feldman, MD, on exciting studies from ASH 2018 regarding the treatment of PTCL

video-image

Frederick Locke, MD, on whether CAR-T therapies will be expanded into solid tumors

video-image

Frederick Locke, MD, on the management of toxicity withs with CAR-T therapies

video-image

Julie Vose, MD, on management of common toxicities with CAR-T therapies

video-image

David Siegel, MD, explains the results of MM014 study presented at ASH

video-image

Julie Vose, MD, discusses improvements made in the delivery of CAR-T therapies in lymphoma

video-image

Frederick Locke, MD, on what improvements to turn around time with CAR-T therapies

video-image

David Siegel, MD, discusses anti-BCMA CAR-T cell therapy for multiple myeloma patients

video-image

Frederick Locke, MD, discusses how to integrate CAR-T with stem cell transplant

video-image

Andre Goy, MD, on responses & outcomes when treating lymphoma with CAR-T therapies

video-image

Tatyana Feldman, MD, shares outcomes of the ECHELON-2 study in PTCL

video-image

David Siegel, MD, talks about the TOURMALINE-MM3 study and the treatment of multiple myeloma

video-image

Tatyana Feldman, MD, offers opinion on the ECHELON-2 study in PTCL

video-image

Frederick Locke, MD, on the use of CAR-T therapies in leukemia and lymphoma

video-image

Tatyana Feldman, MD, on unmet needs in peripheral T-cell lymphoma (PTCL)

video-image

Julie Vose, MD, on if CAR-T therapies are showing impressive results in lymphoma

video-image

Andrew Pecora, MD, tells us about the results of the CPIT trial presented here at ASH

video-image

David Siegel, MD, shares his thoughts on the daratumamab studies presented at ASH 2018

video-image

Julie Vose, MD, tells us about the results of the AUGMENT study in relapsed/refractory indolent NHL

video-image

Julie Vose, MD, discusses whether polatuzumab improves outcomes in DLBCL patients

video-image

Andre Goy, MD, discusses how CAR-T therapies are being integrated into the treatment of large B-Cell lymphoma

video-image

Ravi Vij, MD, on the outcomes of the TOURMALINE-MM3 study in multiple myeloma

video-image

Swaminathan Padmanabhan Iyer, MD, on if ECHELON-2 study is game changing for patients with PTCL

video-image

Peter Vorhees, MD, discusses the outcomes of the GRIFFIN trial in multiple myeloma